Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CFO Lisa Delfini sold 4,350 shares of the stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $2.64, for a total value of $11,484.00. Following the sale, the chief financial officer now directly owns 53,279 shares in the company, valued at $140,656.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Trevi Therapeutics Trading Down 1.6 %
TRVI stock traded down $0.04 during mid-day trading on Friday, reaching $2.50. The company's stock had a trading volume of 431,990 shares, compared to its average volume of 117,115. The company's 50 day moving average is $2.97 and its two-hundred day moving average is $2.14. Trevi Therapeutics, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $4.00. The stock has a market cap of $176.09 million, a PE ratio of -7.35 and a beta of 0.91.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. On average, analysts forecast that Trevi Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.
Analyst Ratings Changes
$16T Crypto Plot From Elon Musk
From Crypto 101 Media | Ad
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Click here now to get your copy.
A number of research firms have recently commented on TRVI. Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 8th. Oppenheimer reiterated an "outperform" rating and issued a $9.00 target price on shares of Trevi Therapeutics in a research report on Thursday, March 21st.
Read Our Latest Stock Analysis on Trevi Therapeutics
Hedge Funds Weigh In On Trevi Therapeutics
Hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD purchased a new position in Trevi Therapeutics during the first quarter worth about $47,000. SG Americas Securities LLC increased its holdings in Trevi Therapeutics by 401.4% in the 4th quarter. SG Americas Securities LLC now owns 98,253 shares of the company's stock valued at $132,000 after purchasing an additional 78,656 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Trevi Therapeutics during the first quarter worth about $208,000. Propel Bio Management LLC acquired a new stake in Trevi Therapeutics in the first quarter valued at approximately $897,000. Finally, Silverarc Capital Management LLC raised its stake in Trevi Therapeutics by 4.7% in the third quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company's stock valued at $2,022,000 after buying an additional 41,491 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
